RJRebekka Vibjerg Jensen

Rebekka Vibjerg Jensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rebekka Vibjerg Jensen has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outcomes after inhospital, subacute, and elective TAVI in COMPARE-TAVI 1

    by Troels Thim, Henrik Nissen, Phillip Freeman, Jordi Sanchez Dahl, Rebekka Vibjerg Jensen, Evald Høj Christiansen, Ashkan Eftekhari, Bjarne Linde Nørgaard, Jonas Agerlund Povlsen, Steen Hvidtfeldt Poulsen, et al.

    Aims: We aimed to compare procedural, echocardiographic, and clinical outcomes within the first year after transcatheter aortic valve implantation (TAVI) among inhospital and subacute patients to elective patients in the COMPARE-TAVI 1 cohort. Methods and results: Among 1030 patients treated with TAVI, 927 (90%) had an elective procedure, 63 (6.1%) had a subacute procedure, and 40 (3.9%) had an inhospital procedure. Procedural characteristics and outcomes were comparable. Among elective, subacute, and inhospital patients, mortality at 30 days was 15 (1.6%), 0 (0%), and 0 (0%) and at 1 year 54 (5.8%), 4 (6.3%), and 2 (5.0%). Stroke at 30 days was 28 (3.0%), 0 (0%), and 3 (7.5%) and at 1 year 42 (4.5%), 5 (7.9%), and 3 (7.5%). New pacemaker at 30 days was 119 (14%), 12 (21%), and 6 (17%) and at 1 year 130 (16%), 14 (25%), and 7 (19%). Elective, subacute, and inhospital patients with LVEF ≤40%, improved their LVEF from 33% (28–37), 33% (27–37), and 28% (22–33) before TAVI to 46% (35–60), 43% (33–52), and 42% (33–55) at 30-days, and 54% (45–62), 53% (43–61), and 49% (39–63) at 1-year. Differences between the groups were not statistically significant. Conclusion: After transfemoral TAVI with balloon-expandable valves in COMPARE-TAVI 1, procedural, echocardiographic, and clinical outcomes were comparable among elective, subacute, and inhospital patients within the first year.


  • Open Access

    Feasibility of coronary alignment in TAVI with balloon-expandable valves: insights from a COMPARE-TAVI 1 substudy

    by Rebekka Vibjerg Jensen, Bjarne Linde Nørgaard, Troels Thim, Evald Høj Christiansen, Jesper Møller Jensen, Christian Juhl Terkelsen

    Background: Coronary alignment may be an important prerequisite for redo-transcatheter aortic valve implantation (TAVI) and may be achieved with balloon-expandable valves (BEV) by intentional orientation of neo-commissures during crimping. Aims: The aim of this study was to evaluate whether coronary alignment is possible during implantation of BEVs and to assess the risk of coronary obstruction limiting the feasibility of redo-TAVI. Methods: On post-TAVI CT scans available in 375 patients enrolled in the COMPARE-TAVI 1 study, we assessed coronary alignment defined by neo-commissure-to-coronary-angles and assessed coverage of coronary ostia by the THV frame and valve-to-aorta distance. Patients were randomized to treatment with Sapien 3 (Group A) or Myval (Group B) with random orientation of neo-commissures during valve crimping (Period 1), or Sapien 3 (Group C) or Myval Octacor (Group D) (Period 2), where intentional orientation of neo-commissures during crimping was attempted according to pre-TAVI CT-scan. Results: Left main alignment or mild misalignment occurred in 50%, 51%, 47%, and 55% of patients in groups A, B, C, and D, P = .33, and right coronary alignment or mild misalignment occurred in 52%, 62%, 54%, and 53%, P = .53. The proportion of patients considered feasible for redo-TAVI defined as a) no coronary coverage by the THV frame, b) coronary coverage but VTA ≥2 mm, or c) coronary coverage and VTA <2 mm but coronary alignment optimal or only mild misalignment, was 81%, 78%, 80%, 87% in groups A, B, C, and D, P = .33. Conclusions: Crimping BEV neo-commissures at predefined angles did not increase coronary alignment; however, the majority of patients treated with BEVs were still considered eligible for redo-TAVI.

  • Myocardial Perfusion Imaging With PET: A Head-to-Head Comparison of 82 Rubidium Versus 15 O-water Tracers Using Invasive Coronary Measurements as Reference

    by Simon Winther, Laust Dupont Rasmussen, Salma Raghad Karim, Jelmer Westra, Jonathan Nørtoft Dahl, Jacob Hartmann Søby, Louise Nissen, Fabian Bøgild Lomstein, Morten Würtz, Jens Munch Sundbøll, et al.

    BACKGROUND: Myocardial perfusion imaging by positron emission tomography (PET) is recommended as a first-line test in stable patients with chest pain symptoms and as a selective second-line test after an abnormal coronary computed tomography angiography (CTA). It is, however, unknown whether the use of Rubidium-82 ( 82 Rb) versus [ 15 O]H 2 O ( 15 O-water) affects the diagnostic performance in coronary artery disease (CAD). The aim of this study was to compare 82 Rb-PET versus 15 O-water-PET head-to-head for diagnosing obstructive CAD. METHODS: The study included consecutive patients (n=1000) referred for CTA with symptoms suggestive of obstructive CAD. Patients with suspected stenosis based on CTA were referred for both 82 Rb-PET, 15 O-water-PET, and subsequently invasive coronary angiography (ICA), including 3-vessel fractional flow reserve and coronary flow reserve measurements. RESULTS: In total, 196/270 (73%) patients with suspected stenosis on CTA completed 82 Rb-PET, 15 O-water-PET, and ICA. Myocardial blood flow measurements from 82 Rb-PET and 15 O-water-PET correlated strongly at rest (ρ, 0.62–0.69) but only moderately during hyperemia (ρ, 0.41–0.59). Only weak correlations were demonstrated between myocardial blood flow reserve by both PET tracers compared with ICA coronary flow reserve (ρ, 0.11–0.38). Hemodynamically obstructive CAD defined as ICA fractional flow reserve ≤0.80, was identified in 86/196 (44%) patients. Using predefined cutoffs, the diagnostic accuracies of 82 Rb-PET versus 15 O-water-PET were similar (sensitivity 69% [58–78%] versus 71% [60–80%], P =0.59; specificity 85% [76–91%] versus 77% [68–85%], P =0.12). Using ICA diameter stenoses >70% as a reference, only 48/196 (24%) patients had anatomically severe CAD, and 82 Rb-PET and 15 O-water-PET sensitivities increased to >85%. CONCLUSIONS: For detection of obstructive CAD by PET myocardial perfusion imaging, 82 Rb versus 15 O-water have similar diagnostic performance. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04707859.


  • Open Access

    Coronary CT angiography instead of invasive angiography before TAVI: Feasibility and outcomes

    by Rebekka Vibjerg Jensen, Jesper Møller Jensen, Nadia Iraqi, Erik Lerkevang Grove, Ole Norling Mathiassen, Kamilla Bech Pedersen, Erik Parner, Jonathon Leipsic, Christian Juhl Terkelsen, Bjarne Linde Nørgaard


  • Open Access

    Short‐Chain Fatty Acid Butyrate Is an Inotropic Agent With Vasorelaxant and Cardioprotective Properties

    by Jacob Marthinsen Seefeldt, Casper Homilius, Jakob Hansen, Thomas Ravn Lassen, Nichlas Riise Jespersen, Rebekka Vibjerg Jensen, Ebbe Boedtkjer, Hans Erik Bøtker, Roni Nielsen

    Background: The heart can metabolize the microbiota‐derived short‐chain fatty acid butyrate. Butyrate may have beneficial effects in heart failure, but the underlying mechanisms are unknown. We tested the hypothesis that butyrate elevates cardiac output by mechanisms involving direct stimulation of cardiac contractility and vasorelaxation in rats. Methods and Results: We examined the effects of butyrate on (1) in vivo hemodynamics using parallel echocardiographic and invasive blood pressure measurements, (2) isolated perfused hearts in Langendorff systems under physiological conditions and after ischemia and reperfusion, and (3) isolated coronary arteries mounted in isometric wire myographs. We tested Na‐butyrate added to injection solutions or physiological buffers and compared its effects with equimolar doses of NaCl. Butyrate at plasma concentrations of 0.56 mM increased cardiac output by 48.8±14.9%, stroke volume by 38.5±12.1%, and left ventricular ejection fraction by 39.6±6.2%, and lowered systemic vascular resistance by 33.5±6.4% without affecting blood pressure or heart rate in vivo. In the range between 0.1 and 5 mM, butyrate increased left ventricular systolic pressure by up to 23.7±3.4% in isolated perfused hearts and by 9.4±2.9% following ischemia and reperfusion, while reducing myocardial infarct size by 81.7±16.9%. Butyrate relaxed isolated coronary septal arteries concentration dependently with an EC 50 =0.57 mM (95% CI, 0.23–1.44). Conclusions: We conclude that butyrate elevates cardiac output through mechanisms involving increased cardiac contractility and vasorelaxation. This effect of butyrate was not associated with adverse myocardial injury in damaged hearts exposed to ischemia and reperfusion.


  • Open Access

    Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent

    by Lars Jakobsen, Evald H. Christiansen, Phillip Freeman, Johnny Kahlert, Karsten Veien, Michael Maeng, Bent Raungaard, Julia Ellert, Steen D. Kristensen, Martin K. Christensen, et al.

    Objectives: To compare the efficacy and safety of the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent (DTS) and the sirolimus‐eluting Orsiro stent (O‐SES) in patients with and without acute coronary syndrome (ACS) included in the SORT OUT X study.Background: The incidence of target lesion failure (TLF) after treatment with modern drug‐eluting stents has been reported to be significantly higher in patients with ACS when compared to patients without ACS. Whether the results from the SORT OUT X study apply to patients with and without ACS remains unknown.Methods: In total, 3146 patients were randomized to stent implantation with DTS (n = 1578; ACS: n = 856) or O‐SES (n = 1568; ACS: n = 854). The primary end point, TLF, was a composite of cardiac death, target‐lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.Results: At 1 year, the rate of TLF was higher in the DTS group compared to the O‐SES group, both among patients with ACS (6.7% vs. 4.1%; incidence rate ratio: 1.65 [95% confidence interval, CI: 1.08–2.52]) and without ACS (6.0% vs. 3.2%; incidence rate ratio: 1.88 [95% CI: 1.13–3.14]). The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without ACSConclusion: Compared to the O‐SES, the DTS was associated with a higher risk of TLF at 12 months in patients with and without ACS. The differences were mainly explained by higher rates of TLR.


  • Open Access

    Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent

    by Lars Jakobsen, Evald H. Christiansen, Phillip Freeman, Johnny Kahlert, Karsten Veien, Michael Maeng, Bent Raungaard, Julia Ellert, Steen D. Kristensen, Martin K. Christensen, et al.

    Objectives: To compare the efficacy and safety of the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent (DTS) and the sirolimus‐eluting Orsiro stent (SES) in patients with and without diabetes mellitus (DM) included in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X study.Background: The incidence of target lesion failure (TLF) after treatment with modern drug‐eluting stents has been reported to be significantly higher in patients with DM when compared to patients without DM. Thus, whether the results from the SORT OUT X study apply to patients with and without DM remains unknown.Methods: In total 3146 patients were randomized to stent implantation with DTS (n = 1578; DM: n = 279) or SES (n = 1568; DM: n = 271). The primary end point, TLF, was a composite of cardiac death, target‐lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 1 year.Results: At 1 year, the rate of TLF was increased in the DTS group compared to the SES group, both among patients with DM (9.3% vs. 4.8%; risk difference: 4.5%; incidence rate ratio: 1.99, 95% confidence interval [CI]: 1.02–3.90) and without DM (5.7% vs. 3.5%; incidence rate ratio: 1.67, 95% CI: 1.15–2.42). The differences were mainly explained by higher rates of TLR.Conclusion: Compared to the SES, the DTS was associated with an increased risk of TLF at 12 months in patients with and without DM. The differences were mainly explained by higher rates of TLR, whereas rates of cardiac death and target lesion MI did not differ significantly between the two stent groups in patients with or without DM.


  • Open Access

    Two case reports of transcatheter valve-in-valve implantation of Sapien 3 and MyVal in degenerated biological tricuspid prosthesis valves

    by Rebekka Vibjerg Jensen, Jesper Khedri Jensen, Evald Høj Christiansen, Mariann Tang, Jens Cosedis Nielsen, Christian Juhl Terkelsen

    Background: Patients with severe tricuspid valve stenosis or dysfunction following degeneration of biological valve prosthesis in tricuspid position are complex, have substantial comorbidity, and very high surgical risk. Case summary: We report two cases with transcatheter tricuspid valve-in-valve implantation in patients with degenerated tricuspid bioprosthesis with transfemoral and transjugular access with Sapien 3 valve and MyVal, respectively. Discussion: In patients with high surgical risk, transcatheter tricuspid valve implantation is a good alternative. Careful consideration of optimal access site, device size, and delivery system is paramount. This case report demonstrates technically feasible and safe transcatheter valve-in-valve implantantion in tricuspid position and highlights the importance of meticulous procedure planning.


  • Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial

    by Lars Jakobsen, Evald H. Christiansen, Phillip Freeman, Johnny Kahlert, Karsten Veien, Michael Maeng, Bent Raungaard, Julia Ellert, Anton B. Villadsen, Steen D. Kristensen, et al.

    Background: Target lesion failure remains an issue with contemporary drug-eluting stents. Thus, the dual-therapy sirolimus-eluting and CD34+ antibody–coated Combo stent (DTS) was designed to further improve early healing. This study aimed to investigate whether the DTS is noninferior to the sirolimus-eluting Orsiro stent (SES) in an all-comers patient population. Methods: The SORT OUT X (Combo Stent Versus Orsiro Stent) trial, was a large-scale, randomized, multicenter, single-blind, 2-arm, noninferiority trial with registry-based follow-up. The primary end point target lesion failure was a composite of cardiac death, myocardial infarction, or target lesion revascularization within 12 months, analyzed using intention-to-treat. The trial was powered for assessing target lesion failure noninferiority of the DTS compared with the SES with a predetermined noninferiority margin of 0.021. Results: A total of 3146 patients were randomized to treatment with the DTS (1578 patients; 2008 lesions) or SES (1568 patients; 1982 lesions). At 12 months, intention-to-treat analysis showed that 100 patients (6.3%) assigned the DTS and 58 patients (3.7%) assigned the SES met the primary end point (absolute risk difference, 2.6% [upper limit of 1-sided 95% CI, 4.1%]; P (noninferiority)=0.76). The SES was superior to the DTS (incidence rate ratios for target lesion failure, 1.74 [95% CI, 1.26–2.41]; P =0.00086). The difference was explained mainly by a higher incidence of target lesion revascularization in the DTS group compared with the SES group (53 [3.4%] vs. 24 [1.5%]; incidence rate ratio, 2.22 [95% CI, 1.37–3.61]; P =0.0012). Conclusions: The DTS did not confirm noninferiority to the SES for target lesion failure at 12 months in an all-comer population. The SES was superior to the DTS mainly because the DTS was associated with an increased risk of target lesion revascularization. However, rates of death, cardiac death, and myocardial infarction at 12 months did not differ significantly between the 2 stent groups. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03216733.


  • Open Access

    Ischemic Heart Disease: An Update

    by Rebekka Vibjerg Jensen, Marie Vognstoft Hjortbak, Hans Erik Bøtker